Background: Loss of skeletal muscle or sarcopenia is commonly seen in various types of malignancy, including ovarian cancer. While some studies suggest sarcopenia as prognostic factor associated with poor survival during chemotherapy, other studies shown no significant association between the two. This meta-analysis aims to investigate whether or not sarcopenia significantly associated with poor survival in ovarian cancer patients undergoing chemotherapy. Methods: A systematic review was conducted using PRISMA guideline. Online databases (PubMed, PubMed Central and Google Scholar) were searched for relevant terms related to sarcopenia in ovarian cancer patients undergoing chemotherapy with overall survival as our outcome in this study. We used Newcastle Ottawa Scale to assess the quality of our studies. Meta-analysis was later performed using Review Software Manager. Results: A total of 4 studies are eligible and therefore included in the analysis. All studies were observational studies consisting 653 patients with ovarian cancer. Our included studies each shows "good" quality according to Newcastle Ottawa Scale. Our meta-analysis showed no significant association between sarcopenia and overall survival in ovarian cancer patients receiving chemotherapy (HR 1.54; 95% CI 0.98-2.42; P ¼ 0.06). Conclusions: Our study result shows that sarcopenia did not influence overall survival of ovarian cancer patients receiving chemotherapy. Future studies should involve a greater number of patients.

No abstract

No abstract

The article discusses the use of the drug bevacizumab in patients with ovarian cancer. АННОТАЦИЯ В статье рассматривается применение препарата бевацизумаб у больных раком яичников.

No abstract